Novo Nordisk Soars, Johnson & Johnson Drops, ServiceNow Falls
On this episode of Stock Movers:- Novo Nordisk (NOVOB) won approval to sell a pill version of its obesity shot Wegovy in the US, to help people lose weight or maintain previous weight loss over the long term. The company will start selling the pill in the US in early January, and it is approved based on the results of the Oasis 4 trial, which found people taking the pill lost about 13.6% of their body weight over 64 weeks.- Johnson & Johnson (JNJ) was ordered to pay about $1.56 billion to a Maryland woman who blamed the company's talc-based baby powder for causing her asbestos-linked cancer.-…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.